Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure

Carcinogenesis

Volumn 18, Issue 1, 1997, Pages 93-96

  Giurgiovich, A J ^a   Diwan, B A ^c   Olivero, O A ^a   Anderson, L M ^b   Rice, J M ^d   Poirier, M C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOCHONDRIAL DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; DISSOCIATION; DRUG DNA INTERACTION; FETUS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LIVER MITOCHONDRION; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RAT;

ANIMALS; CISPLATIN; DNA ADDUCTS; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KIDNEY; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; RATS; RATS, INBRED F344;

EID: 0031410499     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.1.93     Document Type: Article

References (34)

1. J,Diwan,B.A., Anderson.L.M., Ward J.M., Henneman,J.R. and Rice,J.M. (1995) Transplacental careinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol. Appl. Pharmacol., 132, 115-121.
2. Greene,M.H. (1992) Is cisplatin a human carcinogen? J. Natl Cancer Inst., 84, 306-312.
3. Christman,J.E., Teng,N.N., Lebovic,G.S. and Sikic,B.I. (1990) Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. Gynecol. Oncol., 37, 292-295.
4. Barnhart,K.M. and Bowden,G.T. (1985) Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis. Cancer Lett., 29, 101-105.
5. Leopold,W.R., Miller,E.C. and Miller,J.A. (1979) Carcinogenicity of antitumor cis-platinum (II) coordination complexes in the mouse and rat. Cancer Res., 39, 913-918.
6. Hennings,H., Shores,R.A., Poirier,M.C., Reed,E., Tarone,R.E. and Yuspa,S.H. (1990) Enhanced malignant conversion of benign mouse skin tumors by cisplatin. J. Natl Cancer Inst., 82, 836-840.
7. Shamkhani,H. et al. (1994) DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod. Toxicoi., 8, 207-216.
8. Giurgiovich,A.J., Diwan.B.A., Lee,K.B., Anderson,L.M., Rice,J.M. and Poirier,M.C. (1996) Cisplatin -DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure. Carcinogenesis, 17, 1665-1669.
9. Flamm,W.G., Birnstiel,M.L. and Walker,P.M.B. (1967) Preparation and fractionation and isolation of single strands of DNA by ultracentrifugation in fixed-angle rotors. In Birnie,G.D. and Fox,S.M. (eds), Subcellular Components Preparation and Fractionation. Butterworths and Co., London, pp. 126-154.
10. Tamura,K. and Aotsuka,T. (1988) Rapid isolation method of animal mitochondrial DNA by the alkaline lysis procedure. Biochem. Genet., 26, 815-819.
11. Gupta-Burt,S., Shamkhani,H., Reed,E., Tarone,R.E., Allegra,C.J., Pai,L.H. and Poirier,M.C. (1993) Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol. Biomarkers Prevent., 2, 229-234.
12. Schoket,B., Doty,W.A., Vincze,I., Strickland,P.T., Assennato,G. and Poirier,M.C. (1993) Increased sensitivity for determination of polycyclic aromatic hydrocarbon-DNA adducts in human DNA samples by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). Cancer Epidemiol. Biomarkers Prevent., 2, 349-353.
13. Poirier,M.C., Lippard,S.J., Zwelling,L.A., Ushay,H.M., Kerrigan,D., Thill,C.C, Santella,R.M., Grunberger,D. and Yuspa,S.H. (1982) Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc. Natl Acad. Sci. USA, 79, 6443-6447.
14. Reed,E., Gupta-Burt,S., Urterst,C.L. and Poirier,M.C .(1990) Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum(II)-modified DNA. Carcinogenesis, 11, 2117-2121.
15. Wallace,D.C. (1982) Diseases of the mitochondrial DNA. Annu. Rev. Biochem., 26, 1175-1212.
16. Murata,T., Hibasami,H., Maekawa,S., Tagawa,T. and Nakashima,K. (1990) Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem. Int., 20, 949-955.
17. Olivero,O.A. and Poirier,M.C. (1995) Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat. Res., 346, 221-230.
18. Allen,J.A. and Coombs,M.M. (1980) Covalent binding of polycyclic aromatic compounds to mitochondrial and nuclear DNA. Nature, 287, 244-245.
19. Backer,J.M. and Weinstein,I.B. (1980) Mitochondrial DNA is a major cellular target for a dihydrodiol-epoxide derivative of benzo[a]pyrene. Science, 209, 297-299.
20. Niranjan,B.G., Bat,N.K. and Avadhani,N.G. (1982) Preferential attack of mitochondrial DNA by aflatoxin B1 during hepatocarcmogenesis. Science, 215, 73-75.
21. Wilkinson,R. Hawks,A. and Pegg,A.E. (1975) Methylation of rat liver mitochondrial deoxyribonucleic acid by chemical carcinogens and associated alterations in physical properties. Chemico-Biol. Interact., 9, 157-167.
22. Perin-Roussel,O., Perin,E, Barat,N., Plessis,M.J. and Zajdela,F. (1995) Interaction of 7H-dibenzo[r,£]carbazo]e and its organspecific derivatives with hepatic mitochondrial and nuclear DNA in the mouse. Environ. Mol. Mutagen., 25, 202-210.
23. LeDoux,S.P., Wilson,G.L., Beecham,E.J., Stevnsner,T., Wassermann,K. and Bohr,VA. (1992) Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis, 13, 1967-1973.
24. Davis,C.D., Schut,H.A.J. and Snyderwine,E.G. (1994) Adduction of the heterocyclic amine food mutagens IQ and PhIP to mitochondrial and nuclear DNA in the liver of Fischer-344 rats. Carcinogenesis, 15, 641-645.
25. Diwan,B.A., Anderson,L.M., Rehm,S. and Rice,J.M. (1993) Transplacental carcinogenicity of cisplatin: initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice. Cancer Res., 53, 3874-3876.
26. Munoz,E.F., Diwan,B.A., Calvert,R.J., Weghorst,C.M., Anderson,J., Rice,J.M. and Buzard,G.S. (1996) Transplacental mutagenicity of m-platin: H-ras codon 12 and 13 mutations in skin tumors of SENCAR mice. Carcinogenesis, 17, 2741-2745.
27. Sugiyama,S., Hayakawa,M., Kato,T., Hanaki,Y, Shimizu,K. and Ozawa,T. (1989) Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in gluiatnione peroxidase activity. Biochem. Biophys. Res. Commun., 159, 1121-1127.
28. Bogin,E., Marom,M. and Levi,Y. (1994) Changes in serum, liver and kidneys of cisplatin-treated rats: effects of antioxioants. Eur. J. Clin, Chem. Clin. Biochem., 32, 843-851.
29. Zhang,J.G. and Lindup,W.E. (1994) Cisplatin nephrotoxicity: decreases in mitochondria] protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem. Pharmacol., 47, 1127-1135.
30. Aggarwal,S.K. (1993) A histochemical approach to the mechanism of action of cisplatin and its analogues. J Histochem. Cytochem., 41, 1053-1073.
31. Gao,Y, Shimizu,M., Yamada,S., Ozaki,Y and Aso,T. (1993) The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocrin. J., 40, 737-742.
32. 2: evidence for mitochondrial involvement. Cancer Res., 54, 1497-1502.
33. Andrews,P.A. and Albright,K.D. (1992) Mitochondrial defects in cisdiamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res., 52, 1895-1901.
34. Moorehead,R.A., Armstrong,S.G., Wilson,B.C. and Singh,G. (1994) Cross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy. Cancer Res., 54, 2556-2559.